Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

High-density lipoproteins: marker of cardiovascular risk and therapeutic target.

Toth PP, Davidson MH.

J Clin Lipidol. 2010 Sep-Oct;4(5):359-64. doi: 10.1016/j.jacl.2010.08.002. Epub 2010 Aug 17.

PMID:
21122679
2.

Should we target HDL cholesterol level in lowering cardiovascular risk?

Toth PP.

Pol Arch Med Wewn. 2009 Oct;119(10):667-72. Review.

3.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Postgrad Med J. 2008 Nov;84(997):590-8. doi: 10.1136/hrt.2007.125401. Review.

PMID:
19103817
5.

Optimal therapy of low levels of high density lipoprotein-cholesterol.

Kashyap ML, Tavintharan S, Kamanna VS.

Am J Cardiovasc Drugs. 2003;3(1):53-65. Review.

PMID:
14727946
6.

High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.

Besler C, Heinrich K, Riwanto M, Lüscher TF, Landmesser U.

Curr Pharm Des. 2010 May;16(13):1480-93. Review.

PMID:
20196740
7.

Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke.

Walldius G, Jungner I.

Curr Opin Cardiol. 2007 Jul;22(4):359-67. Review.

PMID:
17556890
8.

The antiatherogenic role of high-density lipoprotein cholesterol.

Kwiterovich PO Jr.

Am J Cardiol. 1998 Nov 5;82(9A):13Q-21Q. Review.

PMID:
9819099
9.

Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Hersberger M, von Eckardstein A.

Drugs. 2003;63(18):1907-45. Review.

PMID:
12930163
10.

Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease.

Toth PP.

Curr Cardiol Rep. 2010 Nov;12(6):481-7. doi: 10.1007/s11886-010-0136-3. Review.

PMID:
20740329
11.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401. Review.

PMID:
18480348
12.

[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].

Sertić J, Skorić B, Lovrić J, Bozina T, Reiner Z.

Acta Med Croatica. 2010 Oct;64(4):237-45. Review. Croatian.

PMID:
21688606
13.
14.

The rationale for using apoA-I as a clinical marker of cardiovascular risk.

Barter PJ, Rye KA.

J Intern Med. 2006 May;259(5):447-54. Review.

15.

Managing the risk of atherosclerosis: the role of high-density lipoprotein.

Libby P.

Am J Cardiol. 2001 Dec 20;88(12A):3N-8N. Review.

PMID:
11788123
16.

High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.

Toth PP.

Am J Cardiol. 2005 Nov 7;96(9A):50K-58K; discussion 34K-35K. Epub 2005 Sep 15. Review.

PMID:
16291015
17.

Therapeutic interventions targeted at the augmentation of reverse cholesterol transport.

Toth PP, Davidson MH.

Curr Opin Cardiol. 2004 Jul;19(4):374-9. Review.

PMID:
15218399
18.

High-density lipoprotein metabolism: potential therapeutic targets.

Davidson MH, Toth PP.

Am J Cardiol. 2007 Dec 3;100(11 A):n32-40. Review.

PMID:
18047851
19.

Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes.

Viles-Gonzalez JF, Fuster V, Corti R, Badimon JJ.

Curr Opin Cardiol. 2003 Jul;18(4):286-94. Review.

PMID:
12858127
20.

High-density lipoproteins: multifunctional vanguards of the cardiovascular system.

Marcil M, O'Connell B, Krimbou L, Genest J Jr.

Expert Rev Cardiovasc Ther. 2004 May;2(3):417-30. Review.

PMID:
15151487
Items per page

Supplemental Content

Write to the Help Desk